TAME (Targeting Aging with Metformin)
A series of 14 nationwide clinical trials at 14 U.S. research institutions exploring if metformin can delay the onset of age-related diseases.
View StatusEvidence-Based Healthspan Extension
Separating clinical efficacy from longevity marketing.
We index and evaluate clinical trials, interventional protocols, and medical practitioners focusing on the biology of ageing. Zero brand sponsorships. Just peer-reviewed data.
The State of Longevity, 2024
- Active Trials (Phase II+) 1,429
- Vetted Clinicians 342
- Established Biomarkers 14
The Clinical Triad
Biomarker Analysis
Moving beyond standard metabolic panels to measure epigenetic age, cellular senescence, and proteomic signatures.
View Validated MarkersInterventional Protocols
Evidence grading for pharmacological (e.g., Rapamycin), nutritional, and physical interventions based on human trial data.
Browse Clinical ProtocolsPractitioner Index
A rigorously vetted directory of MDs and DOs actively prescribing and monitoring longevity-focused interventions.
Search the DirectoryThe Efficacy Gap: Human vs. Murine Data
A critical issue in longevity science is the misapplication of mouse-model data to human health. Interventions showing 20%+ lifespan extension in mice frequently fail to demonstrate significant healthspan improvements in human clinical trials.
"Only 11% of promising interventions in preclinical murine models proceed to demonstrate statistically significant geroprotective effects in Phase II human trials."
— Institute for Ageing Research Digest, Vol. 4 (2024)Evaluated Interventions
Current state of evidence for major pharmacological and metabolic interventions.
| Intervention | Target Mechanism | Evidence Tier | Human Trials | Status |
|---|---|---|---|---|
| Rapamycin (Sirolimus) | mTOR Inhibition | Tier II | Phase II Active | Investigational |
| Acarbose | Glucose Regulation | Tier III | Phase IV Approved | Off-label Use |
| NAD+ Precursors (NR/NMN) | Sirtuin Activation | Tier II | Multiple RCTs | OTC Supplement |
| SGLT2 Inhibitors | Metabolic/Renal | Tier III | Phase IV Approved | Off-label Use |
Editorial, Q3 2024
The Supplement Paradox
Why 90% of longevity supplements fail independent lab assays for active ingredients.
The commercial longevity space is currently operating in a regulatory vacuum. Our recent analysis of 50 top-selling NMN and Resveratrol products revealed that over 60% contained less than half of their stated label claims, while 15% contained heavy metal contaminants above safe limits.
This is why the Institute maintains a strict, lab-verified Product Directory. We do not accept affiliate fees or brand sponsorships. Products listed are included solely because they pass independent third-party mass spectrometry and purity tests.
Dr. Sarah Jenkins, PhD
Head of Bio-Assay Analysis
Phenotypic Age Calculator
Calculate your biological age using the Levine PhenoAge model, requiring only 9 standard blood biomarkers. This validated algorithm provides a more accurate reflection of mortality risk than chronological age.
Launch CalculatorFind a Vetted Longevity Practitioner
We have indexed 300+ physicians globally who integrate advanced biomarker testing and geroprotective protocols into clinical practice. Search by location, specialty, and accepted interventions.
142 in US
56 in EU
31 in UK
Latest Clinical Trials
PEARL (Rapamycin for Longevity)
Evaluating safety and efficacy of multiple dosing regimens of rapamycin in healthy older adults over a 12-month period.
View StatusAKG Supplementation Trial
Assessing the impact of Alpha-Ketoglutarate on DNA methylation clocks and physical frailty metrics.
View StatusMETHOD
Rigorous Evaluation Standards
We do not accept funding from supplement companies or longevity clinics. Our evaluations are based entirely on published, peer-reviewed data and independent laboratory assays.
01. Independence
Zero commercial influence. Funded by grants and direct reader support.
02. Human Data Priority
We heavily discount murine data in favor of Phase II/III human trials.
03. Lab Verification
Products must pass blind, third-party mass spectrometry assays.
04. Clinical Consensus
Protocols are verified against active prescribing patterns of vetted MDs.
Essential Biomarkers
ApoB (Apolipoprotein B)
CardiovascularThe primary driver of atherosclerosis. A more accurate marker of cardiovascular risk than LDL-C. Target levels for longevity optimization are often significantly lower than standard reference ranges.
Clinical Target:
<60 mg/dL
Fasting Insulin
MetabolicAn early indicator of insulin resistance, often rising years before fasting glucose or HbA1c become abnormal. Essential for calculating HOMA-IR.
Clinical Target:
<5 uIU/mL
Frequently Asked Questions
What is the difference between healthspan and lifespan?
Lifespan is the total number of years lived. Healthspan is the period of life spent in good health, free from chronic diseases and disability. Most clinical protocols focus on extending healthspan, compressing morbidity into a short period at the end of life.
Why do you not recommend Resveratrol?
Despite early hype in the 2000s based on yeast and mouse models, Resveratrol has consistently failed to demonstrate lifespan extension in the rigorous Interventions Testing Program (ITP), and human clinical data for geroprotection remains weak or contradictory. See our Protocols page for Tier I and II alternatives.
How do I get my supplements tested?
We run batched mass spectrometry tests quarterly. You can nominate products for testing on the Products Directory. We prioritize high-volume, widely used geroprotectors.
The Clinical Update
A zero-fluff, weekly digest of new clinical trial results, protocol adjustments, and practitioner updates. No marketing.